CorriXR Therapeutics Welcomes Jan Case as New COO
CorriXR Therapeutics, Inc., a trailblazing biotherapeutics company dedicated to advancing oncology treatments and combatting drug resistance in solid tumors, has recently announced the appointment of Jan Case as their Chief Operating Officer. This strategic move comes at a pivotal moment for the organization as it prepares to undertake crucial Series A financing and aligns its focus toward initiating its first-in-human clinical trial targeting squamous cell carcinoma of the head and neck.
Jan Case's Extensive Experience
With a robust career spanning over 25 years in the biotechnology and pharmaceutical industries, Case brings a wealth of experience to CorriXR. Before joining CorriXR, she served as the president of Cellicon Valley Consulting, where she played an instrumental role in propelling biotech start-ups, particularly in the realms of cell and gene therapy. Her work focused on facilitating strategic fundraising efforts, enhancing business development initiatives, and optimizing research and development processes for these burgeoning companies.
The Significance of the Appointment
During this critical phase, Eric Kmiec, Ph.D., the CEO of CorriXR, expressed his enthusiasm regarding Jan's onboarding. He stated, "I am pleased to welcome Jan at this key time as we embark on our Series A financing round and advance toward our first-in-human clinical trial to treat squamous cell carcinoma of the head and neck. Her proven skills and expert guidance will help us achieve our goal of significantly improving the lives of people living with cancer." This sentiment highlights the essential expertise that Case adds to the leadership team as they navigate the complexities of clinical trial processes and funding requirements.
Previous Leadership Roles
Prior to her tenure at Cellicon Valley Consulting, Case was part of a pioneering team at Spark Therapeutics. At Spark, she contributed significantly to securing the FDA approval of LUXTURNA, which stands as the first gene therapy approved for a genetic disorder. Additionally, her role was vital in expanding Spark's operational and portfolio reach. Her expansive career also includes more than ten years at Shire Pharmaceuticals (now a subsidiary of Takeda), where she held various leadership positions in program and portfolio management, driving corporate development initiatives.
Educational Background
Jan Case possesses a solid academic foundation that complements her professional prowess. She earned a Bachelor of Science in Biochemistry and Physiology from Southampton University, followed by a Master of Science in Medical Informatics from City University/UMDS in London. Furthermore, she has completed an Executive Continuous Professional Development (CPD) program at the prestigious Wharton School of the University of Pennsylvania, further enhancing her leadership capabilities and strategic insight.
About CorriXR Therapeutics
CorriXR Therapeutics stands out for its commitment to biotherapeutic innovations within oncology. The company leverages its proprietary, IP-protected in vivo gene editing platform to pursue cutting-edge approaches in transforming cancer treatment. As the inaugural biotech spin-out from ChristianaCare and the Gene Editing Institute, CorriXR plays a pivotal role in addressing the challenges of drug resistance, seeking to improve patient outcomes within solid tumor oncology.
Frequently Asked Questions
Who is Jan Case?
Jan Case is the newly appointed Chief Operating Officer of CorriXR Therapeutics, bringing over 25 years of experience in the biotechnology sector.
What is CorriXR Therapeutics focused on?
CorriXR Therapeutics specializes in innovative oncology therapies, particularly in overcoming drug resistance in solid tumors.
What was Jan Case's role at Spark Therapeutics?
At Spark Therapeutics, Jan Case was instrumental in obtaining FDA approval for LUXTURNA, the first gene therapy for a genetic disorder.
What are CorriXR's future plans?
CorriXR Therapeutics is preparing for Series A financing and aims to initiate its first-in-human clinical trials for its oncology treatments.
What educational qualifications does Jan Case have?
Jan Case holds a BSc in Biochemistry and Physiology and an MSc in Medical Informatics, along with a CPD program completion from Wharton.
